MAIA Biotechnology (NASDAQ: MAIA) Completes $33 Million Raise for Phase 3 Cancer Trial
Key Developments MAIA Biotechnology (NASDAQ: MAIA) recently secured approximately $33 million through a common stock offering aimed to finance its pivotal Phase 3 clinical trial. This capital raise is expected to fully fund the company’s ongoing study of its innovative telomere-targeting anticancer therapy, positioning MAIA Biotechnology to advance late-stage clinical development without immediate additional financing needs. The strong investor response to the offering underscores confidence in MAIA Biotechnology’s clinical progress…









